---
layout: default
title: Diclofenac Potassium
parent: 僅模型預測 (L5)
nav_order: 181
evidence_level: L5
indication_count: 0
---

# Diclofenac Potassium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diclofenac Potassium: Drug Repurposing Preliminary Assessment

## One-Sentence Summary

Diclofenac potassium is a non-steroidal anti-inflammatory drug (NSAID) currently marketed in Malaysia with 6 registered products. The TxGNN model has **not yet generated predicted new indications** for this drug, and the evidence pack contains significant data gaps that must be addressed before a full repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | NSAID — specific approved indication text not available in current data |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (Insufficient data for evaluation) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 6 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on well-established pharmacological knowledge, diclofenac potassium is a non-selective cyclooxygenase (COX-1/COX-2) inhibitor belonging to the NSAID class. It exerts its therapeutic effects by inhibiting prostaglandin synthesis, thereby reducing inflammation, pain, and fever. The potassium salt formulation provides faster absorption compared to the sodium salt.

However, **no TxGNN predictions have been generated** for this drug. The `predicted_indications` array is empty, meaning the model has either not yet been run for diclofenac potassium, or the drug was not successfully mapped to the knowledge graph. Without a predicted indication, the mechanistic plausibility analysis cannot be completed.

It is worth noting that diclofenac and the broader NSAID class have been subjects of extensive drug repurposing research globally — particularly in areas such as oncology (colorectal cancer chemoprevention), Alzheimer's disease, and certain dermatological conditions — suggesting that once the TxGNN pipeline is properly configured for this drug, meaningful predictions may emerge.

---

## Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication available for evidence search).

---

## Literature Evidence

Currently no related literature available (no predicted indication available for evidence search).

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|------|------|------|------|
| *(Not available)* | *(Not available)* | *(Not available)* | *(Not available)* |

> **Note:** Although 6 product registrations were identified via the NPRA query (queried 2026-03-27), the detailed licence information (authorization numbers, product names, dosage forms, and approved indications) was not captured in the current evidence pack. This data needs to be re-collected from the NPRA database.

---

## Safety Considerations

> Please refer to the package insert for safety information. Current evidence pack does not contain resolved safety data (warnings, contraindications, or drug-drug interactions). As a widely used NSAID, key safety concerns generally include gastrointestinal bleeding risk, cardiovascular thrombotic events, renal impairment, and hypersensitivity reactions — but these should be confirmed from the official Malaysian package insert.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack is substantially incomplete — there are no TxGNN predicted indications, no resolved DrugBank ID, no mechanism of action data, no safety information, and no detailed licence records. A meaningful repurposing evaluation cannot be conducted until these foundational data gaps are filled.

**To proceed, the following is needed:**

1. **DrugBank mapping** — Resolve the DrugBank ID for diclofenac potassium (likely DB00586 for diclofenac; the potassium salt should map to the parent compound). This is critical for KG-based prediction.
2. **Re-run TxGNN prediction** — Once DrugBank mapping is complete, execute the knowledge graph and deep learning prediction pipelines to generate candidate indications.
3. **Collect NPRA licence details** — Re-query the NPRA database to populate authorization numbers, product names, dosage forms, and approved indication text for all 6 registrations.
4. **Obtain MOA data** — Query DrugBank API for the full mechanism of action, pharmacodynamics, and target information.
5. **Resolve safety data** — Download and parse the Malaysian package insert to extract key warnings, contraindications, and drug interaction information.
6. **Evidence collection** — Once a predicted indication is available, run ClinicalTrials.gov, PubMed, and ICTRP collectors to gather supporting evidence.

---

*Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

